Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

KYMAB LIMITED

Home Clinical Trial Sponsors and OrganizationsKYMAB LIMITED

KYMAB LIMITED

Babraham Hall, Cambridge, United Kingdom

Also known as:

kymouse

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

12

6 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

9

75.0%

Phase 2

2

16.7%

Trial Status Distribution

Active, not recruiting

6

50.0%

Completed

5

41.7%

Terminated

1

8.3%

Clinical Trials

Trials sponsored by this organization (12)

Study Testing Response Effect of KY1005 Against Moderate-to-Severe Atopic Dermatitis, The STREAM-AD Study

Dec 2021390 participants

A Subcutaneous Dose Ranging Study of KY1005 in Patients with Moderate to Severe Atopic Dermatitis

Active, not recruiting

Nov 2021350 participants

A Subcutaneous Dose Ranging Study of KY1005 in Patients with Moderate to Severe Atopic Dermatitis

Active, not recruiting

Nov 2021350 participants

A Phase 1/2, open-label, multi-center study of the safety and efficacy of KY1044 as single agent and in combination with anti-PD-L1 (atezolizumab) in adult patients with selected advanced malignancies

Active, not recruiting

Jan 2021412 participants

A Study of Subcutaneous KY1005 in Healthy Volunteers

Jul 202024 participants

A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies

Jan 2019222 participants

A Study of KY1005 in Patients with Moderate to Severe Atopic Dermatitis

Active, not recruiting

Dec 201889 participants

A Study of KY1005 in Patients With Moderate to Severe Atopic Dermatitis

Dec 201889 participants

Page 1 of 2

Approvals

No approval data available

News

No news articles found

On this page

Overview
Clinical Trials12
Approvals
News

Back to Organizations